ASCO 2020: Implications of the research presented at ASCO 2020 on the treatment of advanced kidney cancer

In this video presentation, Dr Toni Chouieri discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies, all of which were presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Programme.

COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma (RCC).

The phase II OMNIVORE study tested the addition of up to two cycles of ipilimumab in people with advanced RCC who didn’t respond to nivolumab alone, and looked at the duration of nivolumab in responding patients.

SAVOIR is a phase III study of savolitinib versus sunitinib in patients with MET-driven papillary RCC.

Dr Chouieri discusses the future of kidney cancer research and the exploration of combinations of treatments to improve overall survival.

Watch the video interview on UroToday here

Share this Post!


Related post

  TOP